Next Generation Sequencing (NGS) can be used to identify and quantify nucleic acid sequences from all potential adventitious agents and is fast compared to cell-based assays. NIIMBL has initiated a program of work to demonstrate and facilitate adoption of NGS methods for AA testing. In this project, NIIMBL will invest in additional infrastructure to support the NGS test bed, including sequencing platforms and automation to demonstrate NGS more rapidly and robustly for AA testing.
Increase industry and community familiarity with NGS by demonstrating NGS comparability with traditional methods as a faster release assay for vaccines and therapeutics
Help improve the release time of live-saving vaccines and therapeutics in response to coronavirus
Not yet a member? Learn more about which level of NIIMBL membership is right for you and your organization.